1Cabin Hs Clubb KS, Hall C ,et al. Risk for nsystemic embolization of atrial fibrillation without mitral stenosis [ J ]. Am J cardiol, 1990,65(16) :1112-1116.
2Prystowsky EN,Benson JD,Woodrow MD,et al. Management of patients with atrial fibrillation:a statement for heahhcare professionals from the subcommittee on electrocardiography and electrophysiology[ J]. Circulation, 1996,93 (6) : 1262-1277.
3Domanski, M. J. :The epidemiology of atrial fibrillation[ J]. Coronary Krtery Dis,1995,6(1) :9.
4Robinson K, Frenneaux MP, stockins B, et al. Atrial fibrillation inhypertrophic cardiomyopathy: a longitudinal study [J].J Am Coll CardioL,1990,15 (6) :1279-1285.
5Levy S, Breithardt G, Campbell RW, et al, On behalf of the working gronp on arrhythmial of the european society of cardiology,atrial fibrillation;current knowledge and recommendations for management[J]. Eur Heart J,1998,19(9) :1294-1320.
6Prystowsky EN. Management of atrial fibrillation:theraoeutic options and clinical decisions[J]. Am J cardiol,2000,85 (10A) :3 D-11 D.
7Prystowsky EN. Proarrhythmia during drug treatment of supraventricular tachycardia:paradoxical risk of sinus rhythm for sudden death[ J]. Am J Cardiol, 1996,78 ( 1 ) :35-41.
8Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibuiilide for rapid termination of atrial fibrillation and atrial flutter,a dose-response study[ J]. J Am Coll Cardiol, 1996,28 ( 1 ) :130-136.
9Reiftel JA. Drug choices in the treatment of atrial fibfillation[ J]. Am J cardiol,2000,85(10A) :12 D-19 D.
10Zehender M, Hohnloser S, LuLler B, et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation:results of a comparative study and a 2-year follow-up[J]. J Am Coil Cardiol,1992,19(5) :1054-1059.
